A Phase II clinical study of Goserelin combine with Exemestane in premenopausal women with metastatic breast cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-13003946

Enrollment

Unknown

Registered

2013-08-09

Start date

2010-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

1:Goserelin 3.6mg/Month combine with Exemestane 25mg Qd

Eligibility

Sex/Gender

Female

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. receptor (ER / PR) positive metastatic breast cancer; 2. the measurable lesions or evaluable lesions unmeasurable (such as skin lesions or pleural effusion)according to RESIST standards; 3. the patient had undergone TAM treatment (adjuvant therapy or be used after the transfer); 4. premenopausal patients (premenopausal means: normal menstruation or amenorrhea temporarily but E2, FSH, LH were premenopausal range); 5. not be treated by goserelin or aromatase inhibitor.

Exclusion criteria

Exclusion criteria: 1. receptor (ER / PR) negative metastatic breast cancer; 2. the patient had never undergone TAM treatment (adjuvant therapy or be used after the transfer); 3. postmenopausal patients; 4. patients have been treated by goserelin or aromatase inhibitor.

Design outcomes

Primary

Measure	Time frame
objective recurrence rate;	—

Countries

China

Contacts

Public ContactWang Jiayu

Department of Medical Oncology, Cancer Institute/Hospital, CAMS and PUMC

wangjiayu8778@sina.com+86 10 87788114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 4, 2026